• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Open Forum Infect Dis . Effectiveness of the Original Monovalent Coronavirus Disease 2019 Vaccines in Preventing Emergency Department or Urgent Car

tetano

Editor, Senior Moderator
Open Forum Infect Dis


. 2023 Sep 29;10(11):ofad474.
doi: 10.1093/ofid/ofad474. eCollection 2023 Nov. Effectiveness of the Original Monovalent Coronavirus Disease 2019 Vaccines in Preventing Emergency Department or Urgent Care Encounters and Hospitalizations Among Adults With Disabilities: VISION Network, June 2021-September 2022

Palak Patel[SUP] 1 [/SUP], Kristin E Schrader[SUP] 2 [/SUP], Catherine E Rice[SUP] 3 [/SUP], Elizabeth Rowley[SUP] 2 [/SUP], Robyn A Cree[SUP] 3 [/SUP], Malini B DeSilva[SUP] 4 [/SUP], Peter J Embi[SUP] 5 [/SUP], Manjusha Gaglani[SUP] 6 7 [/SUP], Shaun J Grannis[SUP] 8 9 [/SUP], Toan C Ong[SUP] 10 [/SUP], Edward Stenehjem[SUP] 11 [/SUP], Allison L Naleway[SUP] 12 [/SUP], Sarah Ball[SUP] 2 [/SUP], Karthik Natarajan[SUP] 13 14 [/SUP], Nicola P Klein[SUP] 15 [/SUP], Katherine Adams[SUP] 1 [/SUP], Anupam Kharbanda[SUP] 16 [/SUP], Caitlin Ray[SUP] 1 [/SUP], Ruth Link-Gelles[SUP] 17 [/SUP], Mark W Tenforde[SUP] 1 [/SUP]



Affiliations
Abstract

Adults with disabilities are at increased risk for severe coronavirus disease 2019 (COVID-19). Using data across 9 states during Delta- and Omicron-predominant periods (June 2021-September 2022), we evaluated the effectiveness of the original monovalent COVID-19 messenger RNA vaccines among 521 206 emergency department/urgent care encounters (11 471 [2%] in patients with a documented disability) and 139 548 hospitalizations (16 569 [12%] in patients with a disability) for laboratory-confirmed COVID-19 illness in adults (aged ≥18 years). Across variant periods and for the primary series or booster doses, vaccine effectiveness was similar in those with and those without a disability. These findings highlight the importance of adults with disabilities staying up to date with COVID-19 vaccinations.

Keywords: COVID-19; disabilities; test-negative design; vaccine effectiveness.

 
Back
Top Bottom